Eye Bird View on Natural Plants in the Management of Mucormycosis

Authors

  • Amar Patil School of Pharmacy, RK University, Rajkot, Gujarat, India
  • Tushar Desai School of Pharmacy, RK University, Rajkot, Gujarat, India
  • Pravin Tirgar School of Pharmacy, RK University, Rajkot, Gujarat, India

DOI:

https://doi.org/10.25004/IJPSDR.2024.160324

Keywords:

Antifungal activity, Mucormycosis, Herbal medicines, COVID-19-associated mucormycosis

Abstract

Mucormycosis, also referred to as Zygomycosis, is chiefly caused by filamentous molds belonging to the Mucorales group. It can be acquired through inhaling spores, consuming contaminated food, or through injury to the skin. Currently, the second most prevalent fungal infection disease is mucormycosis. It gained greatest attention following the COVID-19 pandemic. The review mainly focuses on several outlines like its history, epidemiology, pathophysiology, types, diagnosis and treatment of mucormycosis. In treatment of mucormycosis, conventional therapy against mucormycosis and some antifungal agents has been discussed. Several diverse contagious ailments were conventionally cured utilizing a widespread series of medicinal plants. Given that India is at the forefront of the Ayurvedic and Siddha medical systems, traditional herbal medicine from India is highly well-known. Antifungal chemicals derived from plants can be a viable option for developing novel and enhanced alternative formulations in the field of antifungal medicine. The main focus of the review is to explore the potential plants having the antifungal activity used for the treatment of mucormycosis. Some of the plants with antifungal activity have been explained, which includes garlic, tea tree oil, aloe vera, thyme, turmeric, neem, eucalyptus, clove, goldenseal, calendula, lavender, guduchi, and oregano. Animal models for mucormycosis study have been explained in the review.

Downloads

Download data is not yet available.

References

Sharma A, Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiologica. 2022;67(3):363–387. Available from: doi.org/10.1007/s12223-021-00934-5

Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: A review of mucormycosis and current pharmacological treatment options: A review of mucormycosis and current pharmacological treatment options. Annals of Pharmacotherapy. 2016;50(9):747–757. Available from: doi.org/10.1177/1060028016655425

Ramalingam S, Narasimhan M, Vinithra K, Janagaraj VD. Mucormycosis: a brief review. Journal of Pure and Applied microbiology Microbiology. 2019;13(1):161–165. Available from: doi.org/10.22207/JPAM.13.1.16

Alom S, Ali F, Md ZK. A comprehensive review on mucormycosis (black fungus) and its association with covid-19. Current Trends Pharmaceutical Research. 2021;8(1):11–40.

Chakravarty J, Gupta MK, Tilak R, Kumar R, Maurya RP, Kumar N, et al. COVID-19-associated Mucormycosis: A clinico-epidemiological study. Journal of Diabetes and its Complications. 2022;36(9):108284. Available from: doi.org/10.1016/j.jdiacomp.2022.108284

Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clinical Microbiology Reviews. 2005;18(3):556–569. Available from: doi.org/10.1128/CMR.18.3.556-569.2005

Veer SM, Bhosale H. COVID-19: Recent Advancement in Black, White and Yellow Mycosis. International Journal of Pharmaceutical Science Invention. 2021;10(5):29–37.

Erami M, Shams-Ghahfarokhi M, Jahanshiri Z, Sharif A, Razzaghi-Abyaneh M. Rhinocerebral mucormycosis due to Rhizopus oryzae in a diabetic patient: a case report. Journal de Mycologie Medicale. 2013;23(2):123–129. Available from: doi.org/10.1016/j.mycmed.2013.04.002

Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses. 2021;64(12):1452–1459. Available from: doi.org/10.1111/myc.13338

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. Journal of Fungi. 2020;6(4):265. Available from: doi.org/10.3390/jof6040265

Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. Journal of Fungi. 2019;5(3):59. Available from: doi.org/10.3390/jof5030059

CD Alert - National Centre for disease Control (NCDC). National Centre for Disease Control (NCDC). 2023 [cited 2024 Apr 16]. Available from: https://ncdc.mohfw.gov.in/cd-alert/

Ish P, Ish S. Prevention of mucormycosis in COVID-19 - the need of the hour. Indian Journal of Ophthalmology. 2021;69(7):1969. Available from: doi.org/10.4103/ijo.IJO120021

Mucormycosis. Who.int. [cited 2024 Apr 16]. Available from: https://www.who.int/india/home/emergencies/coronavirus-disease-(covid-19)/mucormycosis

Subramaniyan V, Fuloria S, Darnal HK, Meenakshi DU, Sekar M, Nordin RB, et al. COVID-19-associated mucormycosis and treatments. Asian Pacific Journal of Tropical Medicine. 2021;14(9):401–409.

Jiang RS, Hsu CY. Endoscopic sinus surgery for rhinocerebral mucormycosis. American Journal of Rhinology. 1999;13(2):105–109. Available from: doi.org/10.2500/105065899782106751

Graves B, Morrissey CO, Wei A, Coutsouvelis J, Ellis S, Pham A, et al. Ananda-Rajah M. Isavuconazole as salvage therapy for mucormycosis. Medical Mycology Case Reports. 2016;11:36–39.

Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: Pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037–1051. Available from: doi.org/10.1002/phar.1652

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. The Lancet Infectious Disease. 2016;16(7):828–837. Available from: doi.org/10.1016/S1473-3099(16)00071-2

Lamoth F, Kontoyiannis DP. Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients. Antimicrobial Agents and Chemotherapy. 2019;63(11) e 01244-19. Available from: doi.org/10.1128/AAC.01244-19

Shubitz LF, Roy ME, Trinh HT, Hoekstra WJ, Schotzinger RJ, Garvey EP. Efficacy of the investigational antifungal VT-1161 in treating naturally occurring coccidioidomycosis in dogs. Antimicrobial Agents and Chemotherapy. 2017;61(5) e00111-17. Available from: doi.org/10.1128/aac.00111-17

Mahomoodally MF. Traditional medicines in Africa: an appraisal of ten potent african medicinal plants. Evidence-Based Complementary and Alternative Medicine. 2013;2013:617459:1-14 Available from: doi.org/10.1155/2013/617459

Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523. Available from: doi.org/10.3390/microorganisms9030523

Aggarwal D, Chander J, Janmeja AK, Katyal R. Pulmonary tuberculosis and mucormycosis co-infection in a diabetic patient. Lung India. 2015;32(1):53–55. Available from: doi.org/10.4103/0970-2113.148452

Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014;57 (3):85–90. Available from: doi.org/10.1111/myc.12243

Fernández-Quintela A, Milton-Laskibar I, Trepiana J, Gómez-Zorita S, Kajarabille N, Léniz A, et al. Key aspects in nutritional management of COVID-19 patients. Journal of Clinical Medicine. 2020;9(8):2589. Available from: doi.org/10.3390/jcm9082589

Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia. 2021;186(2):289–298. Available from: doi.org/10.1007/s11046-021-00528-2

Priya P, Ganesan V, Rajendran T, Geni VG. Mucormycosis in a Tertiary Care Center in South India: A 4-year experience. Indian Journal Critical Care Medicine. 2020;24(3):168–171. Available from: doi.org/10.5005/jp-journals-10071-23387

Malabadi RB, Kolkar KP, Meti NT, Chalannavar RK. Melatonin: One molecule one-medicine for many diseases, coronavirus (SARS-CoV-2) disease (Covid-19); Function in plants. International Journal of Research and Scientific Innovation. 2021;8(3):155–181.

Medeiros de Morais C. Nutritional therapy in COVID-19 management. Kompass Nutrition and Dietetics. 2021;1(1):10–12. Available from: doi.org/10.1159/000512853

Malabadi RB, Nataraja K. Peroxidase activity as a marker of xylogenesis in the culture cell of Psidium guajava Cv. Navaloor Indian Journal Forestry. 2002;25:196–200.

Malabadi RB, Nataraja K. In vitro plant regeneration in Clitoriaternatea Journal of Medicinal and Aromatic Plants 2002;24:733–737.

Malabadi RB, Meti NT, Chalannavar RK. Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19). International Journal of Research and Scientific Innovation. 2021;8(2):191–198.

Malabadi RB, Kolkar KP, Meti NT, Chalannavar RK. Outbreak of Coronavirus (SARS-CoV-2) Delta variant (B. 1.617. 2) and Delta Plus (AY. 1) with fungal infections, Mucormycosis: Herbal medicine treatment. International Journal of Research and Scientific Innovation. 2021;8:59–70.

Sharma S, Sharma A, Gupta U. Molecular Docking studies on the Anti-fungal activity of Allium sativum (Garlic) against Mucormycosis (black fungus) by BIOVIA discovery studio visualizer 21.1. 0.0. Research Square. 2021:1-9.

Sadeghi Zali MH, Yousefi S, Hashempour A, Hashempour N, Seyedgholizadeh S. Evaluation of In Vitro Antifungal Activity of Garlic, Thyme, Aloe Vera, and Cinnamon Essential Oils Against Candida Albicans, Aspergillus Flavus, Aspergillus Niger and Mucor Himalis. Report of Health Care. 2016;2(1):22–28.

Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clinical Microbiology Reviews. 2006;19(1):50–62. Available from: doi.org/10.1128/CMR.19.1.50-62.2006

Homeyer DC, Sanchez CJ, Mende K, Beckius ML, Murray CK, Wenke JC, et al. In vitro activity of Melaleuca alternifolia (tea tree) oil on filamentous fungi and toxicity to human cells. Medical Mycology. 2015;53(3):285–294. Available from: doi.org/10.1093/mmy/myu072

Sevik R, Akarca G, Kilinc M, Ascioglu Ç. Chemical composition of tea tree (Melaleuca alternifolia)(Maiden &Betche) cheel essential oil and its antifungal effect on foodborne molds isolated from meat products. Journal of Essential Oil Bearing Plants. 2021;24(3):561–570.

Shilpa M, Shetty AV, Bhat V, Reddy MSR, Punde P. Antifungal activity of aloe Vera leaf and gel extracts against candida albicans: An in vitro study. World Journal of Dentistry. 2020;11(1):36–40. Available from: doi.org/10.5005/jp-journals-10015-1701

Chen C, Long L, Zhang F, Chen Q, Chen C, Yu X, et al. Antifungal activity, main active components and mechanism of Curcuma longa extract against Fusarium graminearum. PLOS One. 2018;13(3):1-19. Available from: doi.org/10.1371/journal.pone.0194284

Datta S, Sarkar I, Sen G, Sen A. Neem and Turmeric in the management of Covid Associated Mucormycosis (CAM) derived through network pharmacology. Journal of Biomolecular Structure and Dynamics 2023;41(8):3281–3294. Available from: doi.org/10.1080/07391102.2022.2048077

Alzohairy MA. Therapeutics role of Azadirachta indica (neem) and their active constituents in diseases prevention and treatment. Evidence-Based Complementary and Alternative Medicine. 2016;2016:1-16. Available from: doi.org/10.1155/2016/7382506

Soković MD, Vukojević J, Marin PD, Brkić DD, Vajs V, van Griensven LJLD. Chemical composition of essential oils of Thymus and Mentha species and their antifungal activities. Molecules. 2009;14(1):238–249. Available from: doi.org/10.3390/molecules14010238

Mota KS, Pereira FD, Oliveira D, Lima WA, Lima IO. Antifungal activity of Thymus vulgaris L. essential oil and its constituent phytochemicals against Rhizopus oryzae: interaction with ergosterol. Molecules. 2012;17(12):14418–14433.

Tolba H, Moghrani H, Benelmouffok A, Kellou D, Maachi R. Essential oil of Algerian Eucalyptus citriodora: Chemical composition, antifungal activity. Journal de Mycologie Medcale. 2015;25(4):e128-133. Available from: doi.org/10.1016/j.mycmed.2015.10.009

Rana IS, Rana AS, Rajak RC. Evaluation of antifungal activity in essential oil of the Syzygiumaromaticum (L.) by extraction, purification and analysis of its main component eugenol. Brazilian Journal of Microbiology. 2011;42:1269–1277.

Mandal SK, Maji AK, Mishra SK. Goldenseal (Hydrastis canadensis L). and its active constituents: A critical review of their efficacy and toxicological issues. Pharmacological Research. 2020;160:105085. Available from: doi.org/10.1016/j.phrs.2020.105085

Gazim ZC, Rezende CM, Fraga SR, Svidzinski TI, Cortez DA. Antifungal activity of the essential oil from Calendula officinalis L.(Asteraceae) growing in Brazil. Brazilian Journal of Microbiology. 2008;39:61–63. Available from: doi.org/10.1590/S1517-838220080001000015

Bedoya-Serna CM, Dacanal GC, Fernandes AM, Pinho SC. Antifungal activity of nanoemulsions encapsulating oregano (Origanum vulgare) essential oil: in vitro study and application in Minas Padrão cheese. Brazilian Journal of Microbiology. 2018;49(4):929–935. Available from: doi.org/10.1016/j.bjm.2018.05.004

Fd D, Tecca M, Strippoli V, Salvatore G, Battinelli L, Mazzanti G. Antifungal activity of Lavandula angustifolia essential oil against Candida albicans yeast and mycelial form. Medical Mycology. 2005;43(5):391–396. Available from: doi.org/10.1080/13693780400004810

Sharma P, Dwivedee BP, Bisht D, Dash AK, Kumar D. The chemical constituents and diverse pharmacological importance of Tinospora cordifolia. Heliyon. 2019;5(9):1-8 Available from: doi.org/10.1016/j.heliyon.2019.e02437

Ashwini R, Gajalakshmi S, Mythili S, Sathiavelu A. Terminalia chebula-a pharmacological review. Journal Pharmacy and Research. 2011;4(9):2884–2887.

Javed D, Dixit AK, Vats H. Review of published case reports of COVID-19 associated mucormycosis with search of therapeutic potential in Ayurveda and homeopathy. International Journal of Health Sciences and Research. 2021;11(8):114–126. Available from: doi.org/10.52403/ijhsr.20210817

Jacobsen ID. Animal models to study mucormycosis. Journal of Fungi. 2019;5(2):27. Available from: doi.org/10.3390/jof5020027

Seyedmousavi S, Bosco S de MG, de Hoog S, Ebel F, Elad D, Gomes RR, et al. Fungal infections in animals: a patchwork of different situations. Medical Mycology. 2018;56(1):165–187. Available from: doi.org/10.1093/mmy/myx104

Schwartze VU, Jacobsen ID. Mucormycoses caused by Lichtheimia species. Mycoses. 2014;57(3):73–78. Available from: doi.org/10.1111/myc.12239

Kamei K. Animal models of zygomycosis-Absidia, Rhizopus, Rhizomucor, and Cunninghamella. Mycopathologia. 2001;152:05–13.

Jacobsen ID. Mouse models of mucormycosis. Methods Molecular Biology. 2023;2667:181–196. Available from: doi.org/10.1007/978-1-0716-3199-7_14.

Santos D, Fraga-Silva AR, Almeida TF, Santos D, Finato RF, Amorim AC, et al. Rhizopus-host interplay of disseminated mucormycosis in immunocompetent mice. Future Microbiology. 2020;15(9):739–752. Available from: doi.org/10.2217/fmb-2019-0246.

Sarfaty AE, Compton SR, Smith PC, Zeiss CJ. Cutaneous and Pulmonary Mucormycosis in Rag1-and Il2rg-deficient Rats. Comparative Medicine. 2020;70(4):390–395. Available from: doi.org/10.30802/AALAS-CM-20-000015.

Anand VK, Alemar G, Griswold JA Jr. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope. 1992;102(6):656–662. Available from: doi.org/10.1288/00005537-199206000-00011

Waldorf AR, Halde C, Vedros NA. Murine model of pulmonary mucormycosis in cortisone-treated mice. Medical Mycology. 1982;20(3):217–224. Available from: doi.org/10.1080/00362178285380321

Downloads

Published

30-05-2024

Issue

Section

Review Article

How to Cite

“Eye Bird View on Natural Plants in the Management of Mucormycosis”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 16, no. 3, May 2024, pp. 506-1, https://doi.org/10.25004/IJPSDR.2024.160324.